Evaluation of Toxicity in Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumors (NET)
Introduction: Peptide receptor radionuclide therapy (PRRT) is an encouraging systemic treatment for neuroendocrine tumors (NET). PRRT is generally safe and possesses little side effects but little is known about liver toxicity.
Aim(s): Evaluation of potential liver toxicity of PRRT.
Materials and methods: Sixty-one patients underwent PRRT with 177Lu-labeled Dotatate. Thereof 56 had progressing NET, 3 a paraganglioma, and 2 a pheochromocytoma. Blood work was obtained 1 week before each cycle and every 2 months at follow up.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Duan H
To read the full abstract, please log into your ENETS Member account.